Drugs / Filanesib
Trials 8
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT01372540 | Feb 2012 → May 2019 | plasma cell leukemia, plasma cell myeloma | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT01248923 | Dec 2010 → Mar 2016 | plasma cell neoplasm | Array BioPharma | Completed | No outcome recorded |
| Phase 1 | NCT00462358 | Apr 2007 → Nov 2010 | cancer | Array BioPharma | Completed | No outcome recorded |
| Phase 1/23 trials · 1 met primary | ||||||
| Phase 1/2 | NCT02384083 | Sep 2015 → Feb 2018 | plasma cell myeloma | PETHEMA Foundation | Completed | Met primary |
| Phase 1/2 | NCT00821249 | Jan 2009 → Mar 2016 | plasma cell leukemia, plasma cell myeloma | Pfizer | Completed | No outcome recorded |
| Phase 1/2 | NCT00637052 | Mar 2008 → Jun 2010 | acute myeloid leukemia, myelodysplastic syndrome | Pfizer | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT02092922 | May 2014 → Jul 2016 | plasma cell myeloma | Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT01989325 | Nov 2013 → Feb 2016 | plasma cell myeloma | Pfizer | Completed | No outcome recorded |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 10 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Filanesib | “Filanesib (ARRY-520) is a highly selective inhibitor of kinesin spindle protein, which has demonstrated preclinical antimyeloma activity.” PMID 28817190 ↗ Aug 2017 |
| Known as | ARRY-520 | “Kinesin Spindle Protein (KSP) inhibitor Filanesib (ARRY-520) in combination with pomalidomide + dexamethasone” NCT02384083 ↗5“single-agent investigational study drug filanesib (ARRY-520)” NCT02092922 ↗ |
| Known as | Arry-520 hydrochloride | ChEMBL registry synonym — accepted as the source's own label CHEMBL2347655 ↗ |
| Known as | FILANESIB HYDROCHLORIDE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2347655 ↗ |
| Action | Inhibit | “Kinesin-like protein 1 inhibitor” CHEMBL2347655 ↗1“KSP(Eg5) inhibitor” NCT00462358 ↗ |
| Modality | Small molecule | — CHEMBL2347655 ↗ |
| Route | Intravenous | “intravenous” NCT00462358 ↗ |
| Target | KIF11 | “Kinesin-like protein 1 inhibitor” CHEMBL2347655 ↗ |